Microbiome’s Role in Maintaining Health and Preventing Diseases

The Europe human microbiome market is experiencing growth due to increasing awareness among healthcare professionals and the general public about the importance of the human microbiome. The rising understanding of the microbiome's role in maintaining health and preventing diseases has resulted in greater acceptance of microbiome-based products and services. This growing demand drives the market's expansion as individuals actively seek out microbiome-focused interventions for improved health outcomes.

Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/europe-human-microbiome-market

Data Bridge Market Research analyzes that the Europe Human Microbiome Market is growing with a CAGR of 19.9% in the forecast period of 2022 to 2029 and was USD 144.89 million in 2021 and is expected to reach USD 618.60 million by 2029. The significant investment in research and development activities focused on the human microbiome in Europe drives the growth of the market by promoting scientific exploration and discovery, leading to the development of innovative microbiome-based products and therapies.

Key Findings of the Study

Advancements in next-generation sequencing (NGS) technologies are expected to drive the market's growth rate

Advancements in Next-Generation Sequencing (NGS) technologies have significantly impacted the Europe human microbiome market. The improved efficiency and cost-effectiveness of NGS enable comprehensive analysis of the human microbiome, leading to a deeper understanding of its role in health and disease. This knowledge has propelled the development of personalized microbiome-based solutions, including therapeutics and diagnostics, tailored to individual patients. The availability of NGS technologies has accelerated research and product development in the European market, driving its growth and expanding the possibilities for microbiome-focused interventions.

Report Scope and Market Segmentation

Segment Analysis:

Europe human microbiome market is segmented into product, application, technology, type, disease, end users and distributors.

• On the basis of product, the Europe human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, supplements, fecal microbiota transplant, and others.
• On the basis of application, the Europe human microbiome market is segmented into therapeutic and diagnostic.
• On the basis of disease, the Europe human microbiome market is segmented into infectious disease, dermatological disorders, autoimmune disorders, metabolic disorder, gastrointestinal disorders, cancer, mental disorders, c. difficile infection, primary hyperoxyureasolution-phase and others.
• On the basis of technology, the Europe human microbiome market is segmented into genomics, proteomics and metabolomics.
• On the basis of type, the Europe human microbiome market is segmented into small molecule and biologic.
• On the basis of end user, the Europe human microbiome market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, hypermarket/supermarket, clinics and others.
• On the basis of distributor, the Europe human microbiome market is segmented into direct tender and retail sales.

Major Players

Data Bridge Market Research recognizes the following companies as the major Europe human microbiome market  players in Europe human microbiome market  are YSOPIA Bioscience - (France), Evelo Biosciences, Inc. - (U.S.), OptiBiotix HEALTH PLC - (U.K.), Atlas Biomed Group Limited - (U.K.), LUXIA SCIENTIFIC - (France), Ferring B.V. - (Switzerland), Merck KGaA - (Germany),

Market Development

• In November 2021: Seres Therapeutics collaborates with Bacthera to manufacture SER-109 for recurrent Clostridioides difficile infection (rCDI). Bacthera establishes a dedicated facility in its Microbiome Center of Excellence, located on Lonza's Ibex campus in Visp, Switzerland. This collaboration strengthens manufacturing capabilities for LBPs, supporting Seres' efforts in producing therapeutic solutions for rCDI.
• In June 2020: Enterome secures $52.6 million financing to advance its therapeutic pipeline, including EO2401, an innovative 'OncoMimic' cancer immunotherapy. The funding facilitates the progression of clinical development and marks a significant milestone in Enterome's pursuit of effective cancer treatments through its immunotherapy approach.
• In July 2020: OptiBiotix Health PLC launches WellBiome, a groundbreaking ingredient designed to promote digestive, cardiovascular, and metabolic health. WellBiome's introduction reflects OptiBiotix's commitment to developing innovative solutions for improving overall well-being and addresses specific health needs in a comprehensive manner.
• In July 2021: Seres Therapeutics Inc. and Nestlé Health Science form an agreement to jointly commercialize SER-109, an investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the U.S. and Canada. If approved, SER-109 could become the first FDA-approved microbiome therapeutic, providing a groundbreaking solution for CDI treatment.
• In July 2021: 4D pharma plc publishes pre-clinical research on MRx1299, its second-generation immuno-oncology Live Bio therapeutic. The study demonstrates that the bacterium Megasphaera massiliensis or its metabolite pentanoate can enhance the activity of CAR-T therapies and cytotoxic T lymphocytes (CTL) in animal models of cancer, leading to improved tumour clearance. This research showcases the potential of MRx1299 in enhancing anti-tumour activity.

Regional Analysis

Geographically, the countries covered in the Europe human microbiome market report are Germany, U.K., France, Italy, Spain.

As per Data Bridge Market Research analysis:

Germany is the dominant Europe human microbiome market during the forecast period 2022 - 2029

Germany's dominance in the European human microbiome market can be attributed to its significant market share and revenue, which is expected to continue flourishing in the forecast period. The country's high healthcare expenditure, which remains the highest among European Union member states, plays a crucial role in driving market growth. The substantial investment in healthcare infrastructure and research and development activities in Germany creates a favorable environment for the advancement and adoption of human microbiome-based solutions, further strengthening its market position.

For more detailed information about the Europe human microbiome market report, click here – https://www.databridgemarketresearch.com/pt/reports/europe-human-microbiome-market